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ABSTRACT: Cyclic nucleotide phosphodiesterases (PDEs)
decompose second messengers cAMP and cGMP that play
critical roles in many physiological processes. PDE1 of
Saccharomyces cerevisiae has been subcloned and expressed in
Escherichia coli. Recombinant yPDE1 has a KM of 110 μM and a
kcat of 16.9 s
−1 for cAMP and a KM of 105 μM and a kcat of 11.8
s−1 for cGMP. Thus, the specificity constant (kcat/KM
cAMP)/(kcat/
KM
cGMP) of 1.4 indicates a dual specificity of yPDE1 for
hydrolysis of both cAMP and cGMP. The crystal structures of
unliganded yPDE1 and its complex with GMP at 1.31 Å
resolution reveal a new structural folding that is different from
those of human PDEs but is partially similar to that of some
other metalloenzymes such as metallo-β-lactamase. In spite of
their different structures and divalent metals, yPDE1 and human PDEs may share a common mechanism for hydrolysis of cAMP
and cGMP.
Efficient integration of extracellular and intracellular signalsis required to maintain adaptive cellular functions. The
signaling systems of cyclic adenosine and guanosine 3′,5′-
monophosphate (cAMP and cGMP, respectively) represent the
earliest identified signaling pathways in the regulation of a vast
number of critical physiological processes, including visual
transduction, cell proliferation and differentiation, gene
expression, inflammation, apoptosis, steroidogenesis, insulin
secretion, glycogen synthesis, glycogenolysis, lipogenesis, and
lipolysis.1−3 Cyclic nucleotide phosphodiesterases (PDEs) play
important roles in these physiological processes with their
ability to decompose cellular cAMP and cGMP.4−6 Inhibitors
of human PDEs have been widely studied as therapeutics for
the treatment of diseases, such as central nerve system diseases
and cardiomyocyte hypertrophy.7−9 A well-known example of
this drug class is the PDE5 inhibitor sildenafil (Viagra) that has
been approved for the treatment of male erectile dysfunction
and pulmonary hypertension.10,11
The superfamily of PDE can be categorized into two main
classes of nonhomologous proteins that have been known to
specifically hydrolyze cAMP and cGMP, although a third class
of PDE was mentioned but not fully characterized.12 All PDEs
found in mammals and flies belong to class I, while yeast and
protozoans contain classes I and II PDEs. The conserved
catalytic domain of class I PDEs consists of ∼300 amino acids
and contains two divalent metal ions, typically zinc and
magnesium/manganese, to facilitate the catalysis.13 The yeast
genome contains two types of PDEs: yPDE1 and yPDE2. Yeast
PDE2 is a member of the class I PDE superfamily and shares a
similar folding of its catalytic domain with human PDEs,
whereas yPDE1 belongs to the class II PDE superfamily and
uses two zinc ions for its catalysis.14 The sequence alignment
suggests that yPDE1 has a structural folding different from that
of class I PDEs but shares a partially common pattern with
other metalloproteins such as metallo-β-lactamase (MBL).15
Because no three-dimensional structure is available for any
member of class II PDEs, how yPDE1 is evolutionarily related
to class I PDEs and other metalloenzymes remains a puzzle.
The signaling of cAMP in yeast has been shown to play
critical roles in physiological processes, including metabolism,
cell wall biosynthesis, cell growth, and mating.16−23 Over-
expression of the PDE2 gene enhances the tolerance of yeast to
Received: April 4, 2014
Revised: July 8, 2014
Published: July 9, 2014
Article
pubs.acs.org/biochemistry
© 2014 American Chemical Society 4938 dx.doi.org/10.1021/bi500406h | Biochemistry 2014, 53, 4938−4945
Terms of Use
oxidative and ethanol stress for survival.24−26 Both yPDE1 and
yPDE2 appear to participate in the cAMP signaling pathway,
although yPDE2 shows high affinity with a KM of 0.17−1.0 μM
for cAMP,27−30 and yPDE1 has a low affinity with a KM of
100−150 μM.16,31,32 In comparison with numerous publica-
tions about the roles of cAMP in the physiological processes of
yeast, the cGMP signaling pathway has not been well studied,
although it was reported that cGMP activated cAMP-depend-
ent protein kinase of Pichia pastoris yeast.33 There is only one
report showing that yPDE1 from Candida albicans has very
weak cGMP activity with a KM of 250 μM and a Vmax of 0.044
μmol mg−1 min−1, in comparison with a KM of 490 μM and a
Vmax of 1.17 μmol mg
−1 min−1 for cAMP.34 Thus, physiological
roles of the cGMP signaling pathway in yeast remain illusive.
This paper reports the enzymatic properties of full length
yPDE1 and shows that yPDE1 has a dual activity on hydrolysis
of both cAMP and cGMP with similar enzymatic efficacies. The
crystal structure of yPDE1 at 1.31 Å resolution reveals a new
topological folding that is different from those of human PDEs.
■ EXPERIMENTAL PROCEDURES
Subcloning and Protein Purification of Yeast PDE1.
The cDNA of full length yPDE1 (residues 1−369) from bakers’
yeast Saccharomyces cerevisiae was subcloned into vector
pET28a for expression. Oligonucleotide primers containing
the NheI and EcoRI sites were designed and synthesized for
amplification of yPDE1 by polymerase chain reaction.
Amplified yPDE1 cDNA and expression vector pET28a were
separately digested by restriction enzymes NheI and EcoRI,
purified on an agarose gel, and then ligated by T4 DNA ligase.
The resultant pET28-yPDE1 plasmid was confirmed by DNA
sequencing and then transferred into Escherichia coli strain
BL21 (CodonPlus) for expression. When the cells were grown
in 2×YT culture medium at 37 °C to an OD600 of 0.7, 0.1 mM
isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to
induce the overexpression of wild-type yPDE1 at 15 °C for 2
days.
The selenomethionyl mutant of yPDE1 was expressed in M9
minimal medium (6 g of Na2HPO4, 3 g of KH2PO4, 1 g of
NH4Cl, 0.5 g of NaCl, 2 mM MgSO4, 4 g of glucose, 100 mg of
ampicillin, 50 mg of selenomethionine, 100 mg of lysine, 100
mg of threonine, 100 mg of phenylalanine, 50 mg of leucine, 50
mg of isoleucine, and 50 mg of valine per liter). A colony of E.
coli transferred with pET28-yPDE1 was grown in 10 mL of
2×YT medium at 37 °C overnight, centrifuged at 5000 rpm at
room temperature, and then resuspended in 500 mL of
prewarmed M9 medium at 37 °C. After the cells had been
cultured at 37 °C to an OD600 of 0.4−0.5, 0.1 mM IPTG was
added to induce the overexpression at 12 °C for ∼2 days.
The harvested cells were suspended in an extraction buffer of
20 mM Tris base (pH 8.0), 0.3 M NaCl, 15 mM imidazole, and
1 mM β-mercaptoethanol (β-ME) and lysed by being passed
once through a Nano DeBee homogenizer. After centrifugation,
the supernatant was loaded onto a 2.5 cm column containing
10 mL of Ni-nitriloacetic acid (NTA) agarose (QIAGEN). The
column was washed with two buffers [20 mM Tris base (pH
8.0), 15 mM imidazole, and 1 mM β-ME with 50 or 300 mM
NaCl], and then yPDE1 was eluted with 20 mM Tris base (pH
8.0), 50 mM NaCl, 150 mM imidazole, and 1 mM β-ME. After
digestion with thrombin at room temperature for 2 h, the
digested sample was loaded on a Q-Sepharose column (2.5 cm
× 8 cm). The column was washed with ∼100 mL of 20 mM
Table 1. Data Collection and Structural Refinement Statistics
unliganded yPDE1 yPDE1−GMP selenomethionyl yPDE1
Data Collection
space group C2221 C2221 P21
unit cell
a (Å) 73.5 73.7 68.2
b (Å) 85.2 85.2 56.9
c (Å) 130.6 130.8 102.3
β (deg) 106.7
wavelength (Å) 1.075 1.075 0.97920
resolution (Å) 50−1.31 (1.33−1.31) 50−1.31 (1.33−1.31) 50−2.3 (2.38−2.3)
total no. of measurements 1272718 1398700 241585
no. of unique reflections 96740 98268 31820
completeness (%) 98.4 (79.8) 99.3 (88.0) 95.1 (96.1)
average I/σ 12.6 (4.9) 10.1 (2.3) 10.3 (3.5)
Rmerge 0.084 (0.55) 0.064 (0.81) 0.095 (0.501)
Structural Refinement
R-factor/Rfree 0.172/0.184 0.169/0.180
no. of reflections 91848/4844 (5%) 93309/4910 (5%)
resolution (Å) 15−1.31 15−1.31
rmsd
bond lengths (Å) 0.008 0.008
bond angles (deg) 1.2 1.3
average B factor (Å2) (no. of atoms)
protein 18.4 (2914) 18.7 (2914)
MPD 15.2 (8) 19.7 (8)
Zn 13.6 (2) 13.2 (2)
SO4 17.8 (5)
GMP 35.9 (23)
water 25.3 (245) 24.7 (215)
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Tris base (pH 7.5), 50 mM NaCl, 1 mM β-ME, and 1 mM
EDTA and eluted with the same buffer supplemented with 200
mM NaCl. The yPDE1 protein was finally purified with a
Superdex 200 column using a buffer of 20 mM Tris base (pH
7.5), 1 mM β-ME, 1 mM EDTA, and 50 mM NaCl. The
combined yPDE1 fractions were concentrated to 6−10 mg/mL
and stored in −80 °C for use.
Enzymatic Assay. The enzymatic activity was assayed using
[3H]cAMP or [3H]cGMP as a substrate, as previously reported
for human PDE.35 Briefly, yPDE1 was incubated in a reaction
mixture of 50 mM Tris-HCl (pH 7.5) and [3H]cAMP or
[3H]cGMP (20−40K cpm/assay) at room temperature for 15
min. The reaction was terminated by the addition of 0.2 M
ZnSO4. The reaction product [
3H]AMP or [3H]GMP was
precipitated out by addition of 0.2 N Ba(OH)2, while unreacted
[3H]cAMP or [3H]cGMP remained in the supernatant.
Radioactivity in the supernatant was measured by a liquid
scintillation counter. The enzymatic properties were analyzed
by the steady state kinetics. The Michaelis−Menten equation
was used to obtain KM, Vmax, and kcat by nonlinear regression
and also by an Eadie−Hofstee plot.36
The yPDE1 activity was tested in a buffer of 50 mM Tris-
HCl (pH 7.5) and also this plain buffer with 10 mM MgCl2, 2
mM MnCl2, 0.01 mM ZnCl2, 1 mM EDTA, or 1 mM DTT. In
addition, the yPDE1 activity was assayed after dialysis against a
buffer of 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, and 1 mM
EDTA, three times (1 h, 2 h, and overnight).
Crystallization, Structure Determination, and Com-
parison. The crystal of native yPDE1 (6 mg/mL) was grown
by the hanging drop method against a buffer of 20 mM HEPES
(pH 7.5), 5% PEG3350, 40 mM lithium sulfate, and 12% 2-
methyl-2,4-pentanediol (MPD) at room temperature, or a
similar buffer but with 15% glycerol and 20% MPD instead of
12% MPD. The native yPDE1 crystals diffracted to 1.31 Å
resolution and are in space group C2221 with the following cell
dimensions: a = 74 Å, b = 85 Å, and c = 130 Å (Table 1). The
selenomethionyl yPDE1 (11 mg/mL) was crystallized at room
temperature by the hanging drop method against a well buffer
of 6% PEG3350, 30 mM sodium citrate (pH 5.6), 60 mM
ammonium acetate, 75−100 mM ammonium sulfate, and 3%
glycerol. The Se-yPDE1 crystals are in space group P21 with the
following cell dimensions: a = 68 Å, b = 57 Å, c = 102 Å, and β
= 106.7°. The yPDE1−GMP complex was prepared by soaking
the native yPDE1 crystal in the crystallization buffer with 50
mM cGMP at room temperature for 2 days.
The single-wavelength anomalous diffraction (SAD) data for
selenomethionyl yPDE1 were collected at the k-edge of Se (λ =
0.97920), and the data of native yPDE1 and its complex with
cGMP were collected at λ = 1.075 on beamline X29 of the
Brookhaven National Laboratory (Table 1). All the data were
processed with HKL.37 Three Se sites were found for the SAD
data with SHELX and used to phase the structure with
PHENIX.38 Improvement of the SAD phases yielded a figure of
merit of 0.66 for the data at 2.3 Å resolution, and the Fo map
clearly revealed the trace of the yPDE1 structure. The atomic
model was built with O39 and refined with REFMAC.40
The yPDE1 structure was compared with structures in the
Protein Data Bank by the online program Dali (http://www.
ebi.ac.uk/Tools/structure/dalilite). The results were ranked by
Dali’s Z score and rmsd.41 A structure with a Z score of >2.0 is
assumed thought to be partially similar with that of yPDE1, and
a higher Z score indicates better similarity.
■ RESULTS
Yeast PDE1 Hydrolyzes both cAMP and cGMP. The
native bakers’ yeast yPDE1 was shown to contain two zinc ions
per molecule by an atomic absorption spectrometer.16 In a
plain assay buffer without divalent metals, our recombinant
yPDE1 shows similar enzymatic efficacy for hydrolysis of cAMP
and cGMP: KM of 110 μM and kcat of 16.9 s
−1 for cAMP and
KM of 105 μM and kcat of 11.8 s
−1 for cGMP (Table 2). Thus,
the enzymatic efficacy kcat/KM of yPDE1 is 0.153 and 0.113 for
cAMP and cGMP, respectively. The specificity constant (kcat/
KM
cAMP)/(kcat/KM
cGMP) of 1.4 suggests a dual activity of yPDE1
on hydrolysis of both cAMP and cGMP, with a slightly better
efficacy on cAMP than cGMP. Our KM of yPDE1 for cAMP is
comparable with the early report of KM values of 100−120 μM,
but our yPDE1 enzyme is much more active, as shown by a
Vmax at least 20-fold higher than those of the previously
reported proteins.16,31,32
Because human PDEs require magnesium or manganese for
maximization of their activities, a few types of divalent metal
ions were added to the assay buffer to test if they promote the
activity of yPDE1. In summary, addition of 10 μM ZnCl2, 2
mM MnCl2, or 10 mM MgCl2 to the assay buffer did not
significantly promote or inhibit the catalytic activities of our
recombinant yPDE1 upon hydrolysis of cAMP and cGMP
(Table 2). These results are consistent with the early
observations that yPDE1 from S. cerevisiae or C. albicans was
not sensitive to the divalent metals.31,34 In addition, the dialysis
of native yPDE1 against 1 mM EDTA overnight did not change
the catalytic efficacy (kcat/KM) for cAMP but slightly decreased
kcat/KM for cGMP (Table 2), implying that the dialysis was not
efficient for the extraction of the zinc ions that coordinate with
four yPDE1 residues. On the other hand, DTT significantly
inhibits our yPDE1 activity, in contrast to the fact that DTT
promotes the activity of human PDEs.
Architecture of the yPDE1 Structure. The 369 amino
acids of yPDE1 are folded into 16 β-stands, 10 α-helices, and
two 310-helices (Figure 1A). The 16 β-strands can be divided
into two sheets that form a sandwich and a hydrophobic core of
the molecule. The center of the molecular core looks like a
distorted β-barrel and is flanked by the helices. Two molecules
of yPDE1 are tightly associated into a dimer (Figure 1B,C). For
the massive interactions between two monomers, we assume
that the dimeric form of yPDE1 is a biologic unit for its
function. This argument is supported by the gel filtration
experiment in which the recombinant yPDE1 protein appears
to be a dimer in the solution (data not shown) and also by the
structural assembly in which two monomers jointly form the
active site of yPDE1 (Figure 1).
The active site pocket of yPDE1 can be divided into three
portions. The bottom part of the pocket is composed of
residues His128, His130, Asp132, His133, His213, Asp244, and
His326, which are entirely contributed by molecule A of the
dimer. Residues Glu289, Tyr292, His294, and Lys328 of
molecule A constitute one wall of the catalytic pocket, while
Pro142, Tyr145, Trp175, Pro176, and Leu178 of molecule B
form another wall of the pocket (Figure 2A). Two divalent
metal ions sit in the bottom of the pocket, each of which forms
four coordinations with His128, His130, His213, and Asp244,
or with Asp132, His133, Asp244, and His326 of the same
molecule of the dimer (Figure 2B). In addition, a sulfate ion
was found to coordinate with the two zinc ions in the structure
of unliganded yPDE1. This sulfate must come from the excess
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Li2SO4 (40 mM) in the crystallization buffer, and its occupancy
is supported by the clear electron density and a small B factor of
17.8 Å2 comparable with the average value of 18.4 Å2 for
protein atoms. Also, a water molecule or hydroxide ion bridges
both metal ions, to form an octahedral configuration of each
ion (Figure 2B). Because zinc was identified by atomic
absorption spectrometry,31 two zinc ions were assigned for
the structural refinement without further verification. This
assignment is supported by the comparable B factors of the zinc
ions (13.6 Å2) with the overall average B factor of 18.4 Å2 for
protein atoms (Table 1).
Binding of GMP to the yPDE1 Dimer. The unliganded
yPDE1 crystals were soaked in 50 mM cGMP or 25 mM cAMP
for a couple of days. Two data sets were collected from the
soaked crystals to 1.31 Å resolution (Table 1). The Fo − Fc and
2Fo − Fc electron density maps reveal the definite binding and
conformation of GMP in the cGMP-soaked crystal (Figure
2C). However, the structural refinement shows a B factor of
35.9 Å2 for GMP, which is significantly higher than the average
B factor of 18.7 Å2 for protein atoms, suggesting its low
occupancy. This should not be surprising because the product
GMP is expected to weakly bind to yPDE1 on the basis of the
low affinity of substrate cGMP (KM of 104 μM). On the other
hand, the cAMP-soaked crystal shows some electron density at
the binding pocket, but no unique conformation can be
identified.
The phosphate oxygens of GMP chelate with two zinc ions,
form two hydrogen bonds with the side chains of His294 and
Lys328 of molecule A, and also closely contact zinc binding
residues His130, Asp132, His213, Asp244, and His326 of
molecule A of the dimer (Figure 2). The ribose of GMP forms
a hydrogen bond with the side chain of Lys328 of molecule A,
and van der Waals contacts with residues Glu289 and His324 of
molecule A, and Pro142 and Pro176 of molecule B. The
guanine of GMP takes an anti configuration and is located in a
hydrophobic environment that is composed of Val217 and
Tyr292 of molecule A and Tyr145, Pro176, and Leu178 of
molecule B.
Structural Comparison of yPDE1 with Other Metallo-
proteins. The online program Dali41 lists 591 metalloproteins
and/or subunits in the Protein Data Bank (PDB), which have Z
scores of >2 and thus possess similar topological folding,
including ribonuclease Z, tRNA Z, metallo-β-lactamase (MBL),
protein PhnP, cleavage and polyadenylation specificity factor,
RNase J, metal-dependent hydrolase, human 5′-exonuclease
Apollo, coenzyme PQQ synthesis protein B, and human
glyoxalase II, although some of the protein structures contain
manganese or ferric ions, instead of zinc. Dali gives the best Z
score of 24 to ribonuclease Z (PDB entry 2CBN, rmsd of 2.9 Å
for 245 of 306 total residues). However, two zinc ions in
ribonuclease Z are not directly involved in RNA binding but
apparently serve as the structural metals to stabilize the three-
dimensional structure. Thus, the structural similarity between
yPDE1 and ribonuclease Z might just mean a scaffold support
for zinc binding without a functional relationship. Also, on the
top of the Dali list is a MBL-like protein from Gram-negative
Brucella melitensis [PDB entry 3MD7, Z score of 21.4, rmsd of
2.6 Å for 231 of total 270 residues (Figure 3)], although it
contains two manganese ions as the catalytic metals. In the
structure of the MBL-like protein, the low occupancy of GMP
at the Mn binding pocket was identified when the compound
was cocrystallized with GMP-PNP.42 The orientation of GMP
in the MBL-like protein is the opposite of that of GMP inT
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yPDE1, while both of them have the common phosphate
interactions with the divalent metals (Figure 3). Considering
the fact that both MBL-like protein and yPDE1 require a dimer
for catalysis and have identical metal binding residues, yPDE1
might have an evolutionary relationship with the MBL-like
protein. In short, the structural comparison described above
may suggest that the zinc ions in yPDE1 may stabilize and
facilitate the proper folding of the yPDE1 structure, in addition
to their main role as the catalytic ions.
■ DISCUSSION
A Putative Mechanism for the Catalysis of yPDE1. It
has been well established that hydrolysis of a phosphodiester
bond by class I PDEs is accomplished via a nucleophilic attack
of the bridging water or hydroxide ion.43,44 However, it is
unknown whether yPDE1 hydrolyzes cAMP and cGMP with
the same catalytic mechanism as human PDEs. Historically, an
inversion of configuration at phosphorus was proposed for the
stereochemistry of the cAMP hydrolysis by PDE in 1979.45
Later, the crystal structures of PDE443 and PDE9-cGMP44
revealed a hydroxide ion (or a water molecule) that bridges the
divalent metal ions may serve as the nucleophile to attack the
phosphorus. This hydroxide ion may be activated by an aspartic
or glutamic acid (Asp318 or Glu230 in PDE4D2). After
formation of an intermediate covalent bond between the
hydroxide ion and the phosphorus, a histidine (His160 in
PDE4D2) may donate a proton to complete the hydrolysis of
the phosphodiester bond. This model is consistent with the
mechanism of many other zinc enzymes that use an aspartic
acid as a general base to activate a water or hydroxide ion.46
Yeast PDE1 contains two zinc ions as the catalytic metals,
instead of zinc and magnesium or manganese in human PDEs.
The crystal structure reveals a hydroxide ion or water molecule
that bridges two zinc ions of yPDE1, in a pattern similar to that
seen in the case of human PDEs. This hydroxide ion forms a
hydrogen bond with Asp132 and may thus be activated by
Asp132 to initiate the nucleophilic attack (Figures 2B and 4).
After the reaction intermediate forms, His294 that forms a
hydrogen bond with the phosphate group of GMP in the crystal
structure of yPDE1-GMP may serve as the proton donor to
complete the conversion of cGMP to GMP. Therefore, class II
yPDE1 may share a common catalytic mechanism with class I
Figure 1. Structure of yPDE1. (A) Ribbon diagram of monomeric yPDE1. The linker between H1 and B4 (residues 55−63) was disordered. (B)
Dimer of yPDE1. GMP is shown as sticks. Zincs are represented by red spheres. (C) Surface presentation of the yPDE1 dimer. Molecule A (top) is
colored as follows: white for carbon, blue for nitrogen, and red for oxygen. Molecule B is colored cyan.
Figure 2. Active site of yPDE1. (A) GMP (yellow sticks) binding pocket that is constituted with residues from both molecules A (top left, colored
red, blue, and white) and B (bottom right, colored cyan). Dotted lines represent the coordination with zinc ions or hydrogen bonds between GMP
and yPDE1. (B) Six coordinations of each zinc ion in an octahedral configuration. (C) Ribbon diagram of GMP binding. The blue mesh is the
electron density of the Fo − Fc map that was calculated from the structure with omission of GMP and contoured at 2.5σ.
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PDEs for the hydrolysis of cAMP and cGMP, although they
possess different structures and divalent metals.
Implication of the Physiological Roles of yPDE1.
Although class II PDEs are found in a diverse number of
species, including S. cerevisiae, C. albicans, Schizosaccharomyces
pombe, Cryptococcus neoformans, Dictyostelium discoideum,
Leishmania mexicana, Trypanosoma brucei, Vibrio f ischeri, and
Trypanosoma cruzi,47 their physiological roles remain unclear.
The low affinity of cAMP for yPDE1 renders it nonfunctional
at the usual physiological concentration of cAMP. However,
several studies have shown critical roles of yPDE1 under
extreme environments or stresses. Deletion of yPDE1, but not
yPDE2, resulted in a much higher level of accumulation of
cAMP upon addition of glucose or intracellular acidification,
suggesting a specific role of yPDE1 on agonist-induced cAMP
signaling.48 Also, deletion of PDE1 in C. albicans changed the
level of expression of genes, stress responses, cell wall and
membrane biogenesis, adherence, and virulence, suggesting
irreplaceable roles of class II PDEs in stress, adhesion, and
virulence.49 Furthermore, the genetic interactions of PDE1 with
GPA2, a Gα protein controlling yeast differentiation,50 caused
synthetic defects in growth, morphogenesis, and responses to
some stresses, suggesting that yPDE1 and Gpa2 modulate
agonist-induced cAMP signaling.47
While the cAMP signaling pathway of yPDE1 appears to play
a secondary role in yeast physiological processes, the function
of the cGMP signaling pathway in yeast has not been well
characterized. Most studies focused on the cAMP signaling in
which yPDE1 and yPDE2 are involved,16−32 but only a few
papers about the function of the cGMP signaling in yeast have
been published.33,34 Because only the cAMP activity of the four
yPDE2 genes was reported, it is unknown if they also have
cGMP hydrolysis activities. Our study reveals for the first time
that yPDE1 is capable of hydrolyzing both cAMP and cGMP
with similar efficacies. However, it remains to be elucidated
whether the cGMP activity of yPDE1 plays an independent role
in yeast physiological processes or an auxiliary function to the
cAMP signaling pathway.
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■ ABBREVIATIONS
PDEs, phosphodiesterases; cGMP, cyclic guanosine 3′,5′-
monophosphate; cAMP, cyclic adenosine 3′,5′-monophos-
Figure 3. Structural comparison. (A) Superimposition of yPDE1 (cyan
ribbons) over a metallo-β-lactamase-like protein from Gram-negative
B. melitensis (green). Two zinc ions of yPDE1 are shown as red
spheres, while two manganese ions of the bacterium are drawn as blue
spheres. GMP (pink) is from yPDE1, and GMP in the bacterial
structure (yellow) shows an opposite orientation. (B) Detailed view of
GMP binding. The metal binding residues are identical in the two
proteins. The yPDE1 residues are labeled.
Figure 4. Proposed mechanism for yPDE1 catalysis. The catalysis may contain the following steps. (A) The bridging hydroxide ion is activated by
Asp132 and attacks the phosphorus of cGMP. (B) Formation of the intermediate of the reaction. (C) His294 donates a proton to the intermediate.
(D) Completion of the reaction. This mechanism is assumed to apply to the catalysis of cAMP by yPDE1, too.
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phate; β-ME, β-mercaptoethanol; IPTG, isopropyl β-D-1-
thiogalactopyranoside; rmsd, root-mean-square deviation.
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